These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33334146)

  • 1. Maturity onset diabetes of the young and fibrin-related thrombosis risk.
    Sagar RC; Phoenix F; Thanabalasingham G; Naseem K; Ajjan RA; Owen KR
    Diab Vasc Dis Res; 2020; 17(6):1479164120963048. PubMed ID: 33334146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.
    Neergaard-Petersen S; Hvas AM; Kristensen SD; Grove EL; Larsen SB; Phoenix F; Kurdee Z; Grant PJ; Ajjan RA
    Thromb Haemost; 2014 Dec; 112(6):1142-50. PubMed ID: 25187394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
    Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
    Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
    Hooper JM; Stuijver DJ; Orme SM; van Zaane B; Hess K; Gerdes VE; Phoenix F; Rice P; Smith KA; Alzahrani SH; Standeven KF; Ajjan RA
    J Clin Endocrinol Metab; 2012 May; 97(5):1463-73. PubMed ID: 22378816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Plasma Magnesium Levels in Type-1 Diabetes Associate with Prothrombotic Changes in Fibrin Clotting and Fibrinolysis.
    Sobczak AIS; Phoenix FA; Pitt SJ; Ajjan RA; Stewart AJ
    Thromb Haemost; 2020 Feb; 120(2):243-252. PubMed ID: 31942750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystatin C is not a good candidate biomarker for HNF1A-MODY.
    Nowak N; Szopa M; Thanabalasingham G; McDonald TJ; Colclough K; Skupien J; James TJ; Kiec-Wilk B; Kozek E; Mlynarski W; Hattersley AT; Owen KR; Malecki MT
    Acta Diabetol; 2013 Oct; 50(5):815-20. PubMed ID: 22350134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and laboratory clues of maturity-onset diabetes of the young and determination of association with molecular diagnosis.
    Karaoglan M; Nacarkahya G
    J Diabetes; 2021 Feb; 13(2):154-163. PubMed ID: 32710514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
    Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
    Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered plasma fibrin clot properties in essential thrombocythemia.
    Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
    Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
    Kwasny-Krochin B; Gluszko P; Undas A
    Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
    Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
    Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
    McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
    Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
    Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
    Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3.
    Hess K; Alzahrani SH; Price JF; Strachan MW; Oxley N; King R; Gamlen T; Schroeder V; Baxter PD; Ajjan RA
    Diabetologia; 2014 Aug; 57(8):1737-41. PubMed ID: 24838681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.
    Alzahrani SH; Hess K; Price JF; Strachan M; Baxter PD; Cubbon R; Phoenix F; Gamlen T; Ariëns RA; Grant PJ; Ajjan RA
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2282-7. PubMed ID: 22996148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Glomerular Filtration Rate Estimation from Serum Creatinine and Cystatin C in HNF1A-MODY and Other Types of Diabetes.
    Szopa M; Kapusta M; Matejko B; Klupa T; Koblik T; Kiec-Wilk B; Borowiec M; Malecki MT
    J Diabetes Res; 2015; 2015():183094. PubMed ID: 26347889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database.
    Schober E; Rami B; Grabert M; Thon A; Kapellen T; Reinehr T; Holl RW;
    Diabet Med; 2009 May; 26(5):466-73. PubMed ID: 19646184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.